Evidence map›Paper›PMID 35706006›Full record

ArticleJournal of translational medicine2022

Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study.

Benjamin Van Tassell, Virginia Mihalick, Georgia Thomas, Amr Marawan, Azita H Talasaz, Juan Lu, Le Kang, Amy Ladd, Juan Ignacio Damonte, Dave L Dixon and 8 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03797001 (The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure), which is not on this map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03797001 phase2completednot on this map

The Effects of Interleukin-1 Blockade On Exercise Capacity In Patients With Recently Decompensated Systolic Heart Failure

TypeinterventionalSponsorVirginia Commonwealth UniversityRan2019 to 2024Enrolled102ConditionsHeart Failure, Systolic, InflammationArmsAnakinra, Placebo
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Immunometabolism in heart failure.Nature reviews. Cardiology · 2025
    Review
  6. Review
  7. Review
  8. New and future heart failure drugs.Nature cardiovascular research · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Benjamin Van TassellPauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA. bvantassell@vcu.edu.ORCID 0000-0003-0688-4487
Virginia MihalickPauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA.
Georgia ThomasPauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA.
Amr MarawanPauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA.
Azita H TalasazDepartment of Pharmacotherapy and Outcome Sciences, Virginia Commonwealth University, Richmond, VA, USA.
Juan LuDivision of Epidemiology, Department of Family Medicine and Population Health, Virginia Commonwealth University, Richmond, VA, USA.
Le KangDepartment of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA.
Amy LaddPauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA.
Juan Ignacio DamontePauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA.
Dave L DixonPauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA.
Roshanak MarkleyPauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA.
Jeremy TurlingtonPauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA.
Emily FedermannPauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA.
Marco Giuseppe Del BuonoPauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA.
Giuseppe Biondi-ZoccaiDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Justin M CanadaPauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA.
Ross ArenaDepartment of Physical Therapy, College of Applied Science, University of Illinois Chicago, Chicago, IL, USA.
Antonio AbbatePauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA.
Virginia Commonwealth University · USClinica Mediterranea · ITUniversity of Illinois Urbana-Champaign · US

Funding

Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
NCATS NIH HHS UL1 TR002649NHLBI NIH HHS R61/R33HL133943
6 · The paper itself

Abstract

backgroundHeart failure (HF) is a global leading cause of mortality despite implementation of guideline directed therapy which warrants a need for novel treatment strategies. Proof-of-concept clinical trials of anakinra, a recombinant human Interleukin-1 (IL-1) receptor antagonist, have shown promising results in patients with HF.

methodWe designed a single center, randomized, placebo controlled, double-blind phase II randomized clinical trial. One hundred and two adult patients hospitalized within 2 weeks of discharge due to acute decompensated HF with reduced ejection fraction (HFrEF) and systemic inflammation (high sensitivity of C-reactive protein > 2 mg/L) will be randomized in 2:1 ratio to receive anakinra or placebo for 24 weeks. The primary objective is to determine the effect of anakinra on peak oxygen consumption (VO DISCUSSION: The current trial will assess the effects of IL-1 blockade with anakinra for 24 weeks on cardiorespiratory fitness in patients with recent hospitalization due to acute decompensated HFrEF.

trial registrationThe trial was registered prospectively with ClinicalTrials.gov on Jan 8, 2019, identifier NCT03797001.

Indexed as

Heart FailureAdultClinical Trials, Phase II as TopicDouble-Blind MethodHumansInterleukin-1Interleukin 1 Receptor Antagonist ProteinQuality of LifeRandomized Controlled Trials as TopicStroke VolumeTreatment OutcomeInterleukin-1Interleukin 1 Receptor Antagonist ProteinAnakinraHeart failureHFrEFIL-1Interleukin-1Target therapyTreatment

Identifiers

PMID35706006
PMCPMC9198622
OpenAlexW4282914592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.